What are the odds of dying from colorectal cancer?
Evidence quality 4.88/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 4/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 5/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, global adult
1 in 77
1.3% lifetime chance
Most people underestimate this.
range 1 in 125 to 1 in 50
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Colorectal cancer is not as culturally salient as breast or lung cancer — it lacks the ribbon, the celebrity campaigns, and the bodily shorthand of "the lump" or "the cough". Most readers, asked cold, will rank it below both, and below several cancers that actually kill fewer people. At the same time, the intervention story is famously good: colonoscopy is one of the most effective cancer screens in medicine, and public awareness of that fact has been slow to catch up. The recent rise in early-onset disease has further scrambled the mental model of colorectal cancer as "something older men get".
Rough estimate: 50% of US adults are very or somewhat worried about getting cancer (Gallup, all sites); colorectal ranks below breast and lung in unprompted cancer-fear salience
Source: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
Actual
~900,000 colorectal cancer deaths per year globally (~1.9M new cases)
global, all ages, colorectal cancer only
Show derivation
Starts from the IARC GLOBOCAN 2022 global colorectal cancer headline: ~1.9 million new cases and more than 900,000 deaths per year worldwide, making CRC the third most common cancer and the second most common cause of cancer death globally. Spread across a global adult population of ~5.5 billion (age 18+), ~900,000 CRC deaths per year is ~1.6 per 10,000 adults per year. Age-weighted lifetime compounding (CRC mortality is heavily concentrated above age 60, with hazard several times higher in the last third of adult life than at the population average) lands a global adult lifetime CRC-death figure near 1.3%. The direct US number from SEER and ACS-derived estimates is roughly 2% (~1 in 50), driven by higher incidence in high-income countries; see regional_breakdown for the country spread. Headline figure 0.013 (~1 in 77) with an uncertainty band of 1 in 55 to 1 in 125 to reflect the global/US gap plus age-structure sensitivity. Scope is global-adult-lifetime to match the `cancer-lifetime` parent entry; the US figure sits at the top of the band.
Caveats: This is mortality, not incidence: lifetime *incidence* of CRC in the US is rough…
This is mortality, not incidence: lifetime *incidence* of CRC in the US is roughly 3.9% per SEER, and the mortality figure is smaller because CRC is one of the more survivable solid tumors when caught early — 5-year relative survival is ~65% overall and above 90% for localised disease. The "screening works" multiplier above is genuinely one of the largest in cancer prevention, but it is conditioned on actually completing the screen on schedule, not on being eligible. The early-onset trend is real but small in absolute numbers: even after doubling, CRC incidence in adults under 50 is still an order of magnitude below the over-65 rate. The headline lifetime number is dominated by cases in the 60-80 age band, and the doubling-of-early-onset story is a shift in the shape of the age curve, not in the overall scale. Finally, CRC is one of the cancers where the regional gap is partly a diet/lifestyle story and partly a registration and competing-mortality artifact; see the regional_breakdown for the spread.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Global average | 1 in 77 |
~900,000 CRC deaths/yr across ~8B people (IARC GLOBOCAN 2022); age-weighted adult lifetime figure |
| US adult | 1 in 50 |
Direct SEER/ACS figure; ~1 in 50 lifetime, anchored on 3.9% lifetime incidence and ~35-50% long-run case fatality |
| Western Europe | 1 in 56 |
Similar incidence to the US; somewhat lower mortality due to earlier-stage diagnosis in national screening programs |
| East Asia | 1 in 67 |
Rising incidence as diets shift; Japan and South Korea now among the highest-incidence countries, offset by strong screening uptake |
| Sub-Saharan Africa | 1 in 167 |
Lower incidence; confounded by competing mortality (infectious disease, maternal, injury) removing adults from the denominator before peak CRC-risk age |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Colorectal cancer kills more than 900,000 people a year worldwide per the IARC’s GLOBOCAN 2022 release, against roughly 1.9 million new cases — the third most common cancer and the second most common cause of cancer death globally. Age-weighted across a global adult window, that comes to a lifetime mortality figure of roughly 1 in 77. The direct US number from SEER is higher: lifetime incidence of CRC runs ~3.9%, and with 5-year relative survival around 65%, the implied US lifetime CRC-death probability sits near 1 in 50 (about 2%). In the Likelier catalogue CRC lands just below all-cancer lung mortality and just above global breast cancer mortality — the same rough order of magnitude, despite a much quieter cultural profile.
The more interesting number is the one attached to the intervention. Colonoscopy is one of the most effective cancer screens in medicine, and regular screening from age 45 reduces CRC mortality by roughly 60% in compliant populations. That is an unusually large effect size for any population-scale screen, and it is the main reason CRC is tagged here as underrated: not because the raw mortality number is especially high — it sits mid-pack among cancers — but because the gap between “screened on schedule” and “never screened” is larger than the public intuition for what a medical test can do. The USPSTF moved the recommended screening start age from 50 to 45 in May 2021 in response to the early-onset trend documented by Siegel and colleagues in CA: A Cancer Journal for Clinicians.
Where the headline number stops applying: CRC in US adults under 50 has been rising roughly 1-2% per year since the mid-1990s, and the share of cases diagnosed before 55 climbed from 11% in 1995 to 20% in 2019. Mortality in the under-50 group is now rising by 0.5-3% per year even as overall CRC mortality falls by ~2% per year. The causes are not well understood; diet, the gut microbiome, obesity, and environmental exposures are all under active investigation, and none of them currently support a clean personal-risk multiplier. The other large modifiers are genetic (first-degree family history roughly doubles risk; Lynch syndrome pushes the lifetime incidence to 40-80%) and inflammatory (long-standing ulcerative colitis or Crohn’s with extensive colonic involvement is the strongest non-hereditary risk factor). For a reader without those flags, the interesting number to remember is the screening one: the headline lifetime risk moves by roughly 0.4× if the colonoscopy happens on schedule, and roughly 1× if it does not.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] International Agency for Research on Cancer (IARC) / World Health Organization — Colorectal Cancer
Colorectal Cancer- Statistic
More than 1.9 million colorectal cancer cases diagnosed in 2022 and more than 900,000 deaths per year globally; third most common cancer, second most common cause of cancer death- Excerpt
“"In 2022, more than 1.9 million cases were diagnosed... leading to more than 900 000 deaths per year." ”
- Source data from
- 2024-04-04
- Accessed
- 2026-04-11 · archived copy
- Calculation
- GLOBOCAN 2022 headline used directly as the native number. ~900,000 annual global CRC deaths across ~5.5 billion adults is ~1.6 per 10,000 adult-years. Age-weighted over a 60-year adult window — CRC hazard in the 60s and 70s is several times the adult average — gives a lifetime adult-lifetime mortality near 0.013 (~1 in 77). This matches the global column when cross-checked against the direct US SEER estimate (~2%) discounted for lower-incidence regions in the GLOBOCAN regional breakdown.
- Independence
- IARC GLOBOCAN is the upstream dataset used by WHO, ACS international comparisons, and the IHME Global Burden of Disease CRC module. Treat this as the canonical global source; the SEER/ACS US number below is the methodologically independent cross-check.
-
[2] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute — Cancer Stat Facts: Colorectal Cancer
Cancer Stat Facts: Colorectal Cancer- Statistic
Approximately 3.9% of men and women will be diagnosed with colorectal cancer at some point during their lifetime; ~154,270 new cases and ~52,900 deaths estimated for 2025; 5-year relative survival 65.4% (2015-2021)- Excerpt
“"Approximately 3.9 percent of men and women will be diagnosed with colorectal cancer at some point during their lifetime." ”
- Source data from
- 2025-04-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- SEER gives direct lifetime incidence of ~3.9% for the US population. With 5-year relative survival at 65.4%, the implied long-run case-fatality is roughly 35% (a conservative upper bound, since 5-year survival underestimates long-run cure for CRC). 3.9% lifetime incidence × ~35-50% long-run case-fatality yields a US lifetime CRC-death probability of ~1.5-2%, consistent with the "1 in 50" figure commonly cited by ACS. This anchors the US row in the regional breakdown and the top of the Likelier uncertainty band.
- Independence
- SEER (NCI) and IARC GLOBOCAN (WHO) are methodologically independent compilation pipelines. SEER uses US vital registration and population-based cancer registries; IARC aggregates national registry data worldwide. The two agree on scale, and the direct US figure is higher than the global figure by roughly the ratio expected from incidence differences between high-income and lower-incidence regions.
-
[3] Siegel RL, Wagle NS, Jemal A, et al. / CA: A Cancer Journal for Clinicians — Colorectal cancer statistics, 2023
Colorectal cancer statistics, 2023- Statistic
CRC mortality declined 2%/yr from 2011-2020 overall but increased 0.5-3%/yr in adults younger than 50; proportion of cases in adults younger than 55 rose from 11% in 1995 to 20% in 2019- Excerpt
“"CRC mortality declined by 2% annually from 2011-2020 overall but increased by 0.5%-3% annually in individuals younger than 50 years and in Native Americans younger than 65 years." ”
- Source data from
- 2023-03-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Siegel et al. 2023 is the authoritative ACS/SEER-based peer-reviewed summary of CRC trends. Used here to establish (1) the age-weighted distribution of CRC mortality that drives the adult lifetime compounding, (2) the early-onset trend that motivated the USPSTF screening-age change, and (3) the overall ~2%/yr decline in total CRC mortality, which means the headline lifetime figure is slowly drifting down even as the early-onset segment rises.
- Independence
- Uses SEER incidence data and NCHS mortality data — same upstream as the SEER Stat Facts source above. Treat as a dependent but methodologically richer analysis of the same pipeline rather than an independent verification.
-
[4] US Preventive Services Task Force — Final Recommendation Statement: Colorectal Cancer: Screening
Final Recommendation Statement: Colorectal Cancer: Screening- Statistic
USPSTF recommends CRC screening for all adults 45-75 (Grade B for 45-49, Grade A for 50-75); lowered from age 50 to age 45 in May 2021- Excerpt
“"The USPSTF now recommends offering screening starting at age 45 years." ”
- Source data from
- 2021-05-18
- Accessed
- 2026-04-11 · archived copy
- Calculation
- USPSTF is the authoritative US primary-care screening guideline. The 2021 move from age 50 to age 45 was a direct response to the early-onset trend documented by Siegel et al. and the SEER data. Used here to anchor the "screening works" claim and the screening-from-45 multiplier in personal_factor_multipliers.
- Independence
- USPSTF evidence synthesis is methodologically independent of SEER/IARC incidence tracking — it aggregates RCT and cohort evidence on screening effectiveness, not incidence registry data.
-
[5] National Cancer Institute (NCI) — Colorectal Cancer Rising among Young Adults
Colorectal Cancer Rising among Young Adults- Statistic
CRC incidence has been rising steadily among adults younger than 50 since the 1990s; several organizations have lowered screening age from 50 to 45- Excerpt
“"Since the 1990s, the rate of colorectal cancer (which includes cancers of the colon and rectum) has been rising steadily among adults younger than 50." ”
- Source data from
- 2020-11-05
- Accessed
- 2026-04-11 · archived copy
- Calculation
- NCI blog summarizing the early-onset CRC trend for a general audience, used as a plain-English cross-check on the Siegel 2023 peer-reviewed figures. Confirms that the doubling of CRC incidence in adults under 50 since the early 1990s is the established consensus view at NCI.
- Independence
- Draws on the same SEER incidence data pipeline as Siegel 2023 and SEER Stat Facts. Used as an authoritative plain-English citation, not as an independent verification.